Phase 3 Multicenter, Randomized, Open-label, Active-Controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

ABX-EGF, Bevacizumab, Fluorouracil (5-FU), Irinotecan, Leucovorin, Panitumumab, Sotorasib

Principal Investigator(s):

Eng, Cathy

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-11-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTGIT23266

National Clinical Trial ID:

NCT06252649

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available